Compare Stocks: KPRX, ATHE, RFAI, and VERU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$4.70 +3.3%	$4.77	$2.66 ▼ $5.89	$40.30M	0.27	9,798 shs	5,928 shs
KPRX Kiora Pharmaceuticals	$2.62 +1.6%	$2.56	$1.76 ▼ $3.01	$11.41M	-0.38	23,176 shs	12,468 shs
RFAI RF Acquisition Corp II	$11.09 -0.3%	$11.05	$10.58 ▼ $11.44	$92.78M	N/A	48,641 shs	1,559 shs
VERU Veru	$2.79 +0.7%	$2.73	$2.05 ▼ $7.33	$44.46M	-1.15	297,005 shs	454,272 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+0.39%	+2.76%	-15.60%	-5.11%	-15.13%
KPRX Kiora Pharmaceuticals	-2.27%	-0.39%	+2.79%	+5.74%	+9.32%
RFAI RF Acquisition Corp II	+0.59%	+0.53%	+0.68%	+1.78%	+4.90%
VERU Veru	+18.88%	+22.57%	-0.36%	+22.03%	+643.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$4.70 +3.3%	$4.77	$2.66 ▼ $5.89	$40.30M	0.27	9,798 shs	5,928 shs
KPRX Kiora Pharmaceuticals	$2.62 +1.6%	$2.56	$1.76 ▼ $3.01	$11.41M	-0.38	23,176 shs	12,468 shs
RFAI RF Acquisition Corp II	$11.09 -0.3%	$11.05	$10.58 ▼ $11.44	$92.78M	N/A	48,641 shs	1,559 shs
VERU Veru	$2.79 +0.7%	$2.73	$2.05 ▼ $7.33	$44.46M	-1.15	297,005 shs	454,272 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+0.39%	+2.76%	-15.60%	-5.11%	-15.13%
KPRX Kiora Pharmaceuticals	-2.27%	-0.39%	+2.79%	+5.74%	+9.32%
RFAI RF Acquisition Corp II	+0.59%	+0.53%	+0.68%	+1.78%	+4.90%
VERU Veru	+18.88%	+22.57%	-0.36%	+22.03%	+643.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$10.00	112.77% Upside
KPRX Kiora Pharmaceuticals	2.00	Hold	$10.00	281.68% Upside
RFAI RF Acquisition Corp II	2.00	Hold	N/A	N/A
VERU Veru	2.50	Moderate Buy	$23.00	724.37% Upside

Current Analyst Ratings Breakdown

Latest KPRX, ATHE, RFAI, and VERU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ATHE Alterity Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
8/11/2026	ATHE Alterity Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$2.00
8/11/2026	ATHE Alterity Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/7/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/5/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ATHE Alterity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	ATHE Alterity Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$16.00
6/26/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$3.10 per share	N/A
KPRX Kiora Pharmaceuticals	$16.02M	0.72	N/A	N/A	$4.38 per share	0.60
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A
VERU Veru	$16.89M	2.65	N/A	N/A	$1.25 per share	2.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$7.87M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/28/2026 (Estimated)
KPRX Kiora Pharmaceuticals	-$10.84M	-$2.51	N/A	N/A	N/A	N/A	-62.81%	-43.74%	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VERU Veru	-$22.73M	-$0.89	N/A	N/A	N/A	N/A	-46.91%	-35.13%	N/A

Latest KPRX, ATHE, RFAI, and VERU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q4 2026 TU	ATHE Alterity Therapeutics	-$0.0418	N/A	N/A	N/A	$2.32 million	N/A
8/10/2026	Q3 2026	VERU Veru	-$0.32	-$0.30	+$0.02	-$0.30	$1.70 million	N/A
8/7/2026	Q2 2026	KPRX Kiora Pharmaceuticals	-$0.47	-$0.34	+$0.13	-$0.34	N/A	N/A
8/7/2026	Q2 2026	RFAI RF Acquisition Corp II	N/A	$0.01	N/A	$0.01	N/A	N/A
5/13/2026	Q2 2026	VERU Veru	-$0.2850	-$0.13	+$0.1550	-$0.12	$1.90 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	21.97	N/A
KPRX Kiora Pharmaceuticals	N/A	6.68	6.68
RFAI RF Acquisition Corp II	N/A	N/A	N/A
VERU Veru	N/A	6.19	6.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
KPRX Kiora Pharmaceuticals	76.97%
RFAI RF Acquisition Corp II	N/A
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
KPRX Kiora Pharmaceuticals	0.52%
RFAI RF Acquisition Corp II	39.10%
VERU Veru	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
KPRX Kiora Pharmaceuticals	10	4.42 million	4.41 million	Not Optionable
RFAI RF Acquisition Corp II	N/A	8.34 million	5.08 million	N/A
VERU Veru	230	16.05 million	13.77 million	Optionable

KPRX, ATHE, RFAI, and VERU Headlines

Recent News About These Companies

Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients

August 10 at 6:23 PM | seekingalpha.com

Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239

August 10 at 7:11 AM | quiverquant.comQ

Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline

August 10 at 6:51 AM | quiverquant.comQ

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

August 10 at 6:30 AM | globenewswire.com

Canaccord Genuity Group Forecasts Veru Q3 Earnings

August 10 at 1:13 AM | americanbankingnews.com

Veru (VERU) Projected to Post Quarterly Earnings on Monday

August 9 at 2:56 AM | americanbankingnews.com

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

August 4, 2026 | globenewswire.com

Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update

August 3, 2026 | quiverquant.comQ

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

August 3, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

July 30, 2026 | globenewswire.com

Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity

July 27, 2026 | quiverquant.comQ

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

July 27, 2026 | globenewswire.com

Palisade's Dan Veru talks his small cap trading playbook

July 12, 2026 | cnbc.com

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

July 7, 2026 | globenewswire.com

Veru Establishes At-the-Market Equity Offering Program

July 2, 2026 | tipranks.com

Veru to Conduct Enobosarm Clinical Study With Novo Nordisk's Weight-Loss Pill Wegovy

June 5, 2026 | marketwatch.com

Veru And 2 Other Intriguing Penny Stocks To Watch

June 5, 2026 | finance.yahoo.com

Veru (VERU) surges 161.8% after disclosing Novo Nordisk Wegovy supply deal for obesity study

June 4, 2026 | quiverquant.comQ

Veru, Novo Nordisk partner on enobosarm-Wegovy trial

June 4, 2026 | tipranks.com

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

May 29, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KPRX, ATHE, RFAI, and VERU Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$4.70 +0.15 (+3.30%)

Closing price 03:59 PM Eastern

Extended Trading

$4.70 0.00 (0.00%)

As of 07:34 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.62 +0.04 (+1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$2.60 -0.02 (-0.57%)

As of 04:10 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

RF Acquisition Corp II NASDAQ:RFAI

$11.08 -0.04 (-0.35%)

As of 04:00 PM Eastern

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

Veru NASDAQ:VERU

$2.79 +0.02 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$2.80 +0.00 (+0.18%)

As of 07:59 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KPRX, ATHE, RFAI, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KPRX, ATHE, RFAI, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KPRX, ATHE, RFAI, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KPRX, ATHE, RFAI, and VERU Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

Kiora Pharmaceuticals NASDAQ:KPRX

RF Acquisition Corp II NASDAQ:RFAI

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KPRX, ATHE, RFAI, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KPRX, ATHE, RFAI, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KPRX, ATHE, RFAI, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KPRX, ATHE, RFAI, and VERU Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

Kiora Pharmaceuticals NASDAQ:KPRX

RF Acquisition Corp II NASDAQ:RFAI

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools